Oppenheimer bullish on OPKO “Investors underestimate” Upside
Pharma company of Philip Frost gets warm recommendation today from Oppenheimer’s Research Department, began to cover on recommendation of ‘Outperform’
Research Department at Oppenheimer started today covering the stock Opko Health.
A recommendation of ‘Outperform’ with a target price of $ 13, meaning upside of nearly 40% over yesterday’s closing price.
Analysts explain the target price sums up all parts “because the company has a wide range of products.”
Looking ahead, Oppenheimer marks a number of key products.
Opko Health is expected to launch two diagnostics products in 2015, and two pharma products in 2016, which we believe to be the most significant valuation,” write the research department.
They point out that the main focus should be on the diagnostic products, especially 4Kscore and Claros-1, although Opko is known more for its drug pipeline.
Overall perspective, Oppenheimer assessment is that investors underestimate their assessment of the potential of 4Kscore, and they expect that the product will expand well beyond the target market it is targeting.
The 4Kscore intended to diagnose prostate cancer, is expected to market to about a million customers, and will also in the long term a much broader market of about 30 million customers, according to Oppenheimer.
Analysts estimate that the 4Kscore has a value of about $ 5 per share.
Other products that add value are Claros-1 (a value of $ 2.5 per share), Rayaldy in a Phase 3 clinical trial right now (about $ 4 per share) and hGH-CTP ($ 1.5) per share.
Now give a PE and throw in SQUEEEZ and $30?????????????????????????????????????
